Medicilon Supports Moon Biotech’s Groundbreaking MNO-863 Probiotic Drug – Achieves Nearly 10% Weight Loss in 4 Weeks and Secures Dual Clinical Trial Trial Approvals
2025-04-18 Moon Biotech recently has announced that its innovative probiotic drug, MNO-863 enteric-coated capsules, has been approved for clinical trials by China’s NMPA. This follows earlier approval from the U.S. FDA, marking a rare dual greenlight across both major regulatory bodies. Medicilon is proud to have been a trusted R&D partner in this achievement, […]
Zero Defects! Medicilon Supports MeiJi BioPharma’s Oral Paclitaxel Soft Capsule in Gaining FDA IND Approval
2025-04-11 Meiji BioPharma has received FDA approval for its IND application for an oral paclitaxel soft capsule with “zero defects.” This marks the world’s first and only oral paclitaxel soft capsule project to receive clinical trial approval. Medicilon as a long-term partner of Meiji BioPharma, provided comprehensive preclinical R&D services, including formulation development, pharmacodynamics, […]
Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance
On February 26, Tyercan announced that its independently developed first-in-class drug, Tye1001, received clinical trial approval from China’s NMPA, following its approval by the US FDA on July 12, 2024. This marks a significant milestone of dual approval in both China and the US. As Tyercan’s partner, Medicilon delivered comprehensive GLP-compliant preclinical services, including pharmacodynamics, […]
Medicilon Supports Partner Nuoyuan Medical Equipment Co., Ltd. in Securing FDA IND Approval for Class 1 Innovation Drug Pemefolacianine
2025-01-07 On December 20, Nanjing Nuoyuan Medical Devices Co., Ltd. (“Nuoyuan Medical”) received FDA approval for an IND application for Pemefolacianine, an innovative Class 1 drug. This marks the first FDA IND approval for a folate receptor-targeted imaging agent developed in China, following Cytalux (OTL-38), the world’s first FDA-approved agent of its kind. Pemefolacianine has […]
A Decade of Collaboration: Medicilon Supports SinoRDA in Achieving Approval for Linaprazan Glurate
2025-01-02 On December 3, Shanghai SinoRDA Science and Technology Co., Ltd., a subsidiary of Guizhou SinoRDA Biotechnology Co., Ltd. (SinoRDA), secured approval from the National Medical Products Administration for its Linaprazan Glurate capsules. This milestone drug, a Category 1 chemical medication, is designed to treat reflux esophagitis. Medicilon, a trusted partner of SinoRDA for over a […]
Medicilon Supports Strategic Partner CGeneTech in Achieving Approval for Next-Generation DPP-4 Inhibitor
2025-01-02 CGeneTech Biopharmaceutical Technology (Suzhou) Co., Ltd. (“CGeneTech”) recently marked a significant milestone with the approval of its innovative Class 1 drug, Sentagliptin Phosphate tablets, for marketing in China. As a strategic partner, Medicilon provided comprehensive preclinical research services that complied with GLP standards, encompassing pharmacodynamics, pharmacokinetics, safety evaluations, and biomarker bioanalysis in Phase I clinical trials. Medicilon’s reliable research system—demonstrating high consistency […]
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon’s technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Lilly Xu Chief Technology Officer of Medicilon […]
Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
2024-12-03 Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval. Medicilon, as a trusted partner, provided pharmacokinetic studies and GLP-compliant safety evaluations, playing an instrumental role in advancing the drug development process. JM045: A New Hope for Prostate Cancer Patients JM045 is a gonadotropin-releasing hormone (GnRH) analog […]
Medicilon Boston’s Second R&D Center Grandly Sets Sail
2024-11-19 On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets. This achievement elevates Medicilon’s position as a competitive force in the pharmaceutical landscape while highlighting its dedication to quality and collaboration. The launch event brought […]
Medicilon Supports Jemincare’s JMX-2002 Liposome Injection Clinical Trial Approval
2024-12-09 Shanghai, China – October 16, 2024 – Medicilon is pleased to announce that its long-term partner, Jemincare Group Co., Ltd. (“Jemincare”), has received clinical trial approval from the China National Medical Products Administration (NMPA) for its innovative liposome injection drug, JMX-2002, for the treatment of solid tumors, including non-small cell lung cancer and breast cancer. […]
